Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

1. Why am I using Herceptin SC? Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to treat breast cancer whose tumour has tested positive to HER2. For more information ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD. Developed by Korean biosimilar specialists Samsung Bioepsis, MSD is the ...

Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab) – already facing lower-cost competition in the US and Europe – and Perjeta (pertuzumab), which are both ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co ...